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Summary With new drugs being introduced to treat asthma it is timely to review
criteria that can be used to assess efficacy in clinical trials. Anti-asthma drugs are
classified into symptoms-modifying, symptom preventers and disease modifying
agents. Attention is drawn to the types of experimental evidence required in
preclinical studies to support further clinical development of a new therapy. Clinical
trials demand careful selection of patients to maximise the strength of the efficacy
signal according to the type of trial being designed. While provocation tests are
useful in suggesting efficacy, negative tests do not necessarily indicate lack of anti-
asthma activity. Therapeutic trial designs need to take account of duration of
treatment, dose–response relationships and confirmatory trials. Outcome measures
include symptoms, lung function, reduction in concomitant medication, exacerba-
tions, quality of life and measures of inflammation. Interpretation of results need to
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include the clinical relevance of any changes as well as statistical significance.
Special consideration needs to be given to the evaluation of drugs for acute severe
asthma, asthma in children and older people, co-morbidity such as rhinitis, and
inhaler devices. As with all drugs introduced into practice, careful attention needs
to be paid to both short- and long-term safety.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Asthma is a chronic inflammatory disorder of the
airways resulting in airway re-modelling with
increased responsiveness to exogenous and endo-
genous stimuli and variable airflow limitation.1,2 In
its typical form, asthma has its onset in early
childhood and presents with symptoms of wheez-
ing, breathlessness and cough, occurring either
spontaneously or in response to external stimuli.
The disease has a varying natural history, ranging
from a transient disease of childhood through to
persistent severe disease throughout life.
In childhood, asthma is frequently associated
with atopy (the predisposition to develop immu-
noglobulin-E against specific allergens) and is
associated with other features of atopy, including
eczema, rhinitis and sinusitis. Late onset asthma
may occur in association with sensitisation to
occupational exposures involving either IgE or
non-IgE mechanisms or in the absence of any known
stimulus (intrinsic or cryptogenic asthma).
It is conceivable that, in the future, asthma may
not be defined as a single disease entity but will be
recognised as a number of distinct conditions of
differing aetiology, sharing a similar pattern of
symptoms.
International treatment guidelines have been
established for the management of the condition.
In the development of new treatments specific
aspects need to be considered and these include:
* the present classification of drugs used for the
management of asthma.
* disease severity and the impact of this in clinical
trials.
* appropriate trial design and duration.
* appropriate use of endpoints and their duration
(including exacerbations).
* evaluation of efficacy and clinical validity.
* special populations, including children and el-
derly.
* evaluation of safety.
The aim of present international treatment
guidelines is to control asthma by reducing under-
lying lung inflammation, improving symptoms and
preventing exacerbations.
Objectives and nomenclature
The objectives of drug development in asthma can
be divided into four categories:
(i) Prevention of asthma in individuals at risk.
(ii) Prevention of symptoms, exacerbations and
further complications including morbidity and
mortality.
(iii) Treatment of symptoms and exacerbations.
(iv) Cure of the disease, defined as the absence
of symptoms, exacerbations, and variable
airflow limitations one year after stopping
treatment.
Only objectives (ii) and (iii) are currently attain-
able, but advances in our knowledge of the
aetiopathogenesis of the disorder, together with
novel therapeutic approaches (pharmacogenetics,
therapeutic vaccination, immunomodulatory agents)
may allow studies addressing (i) and (iv) in the
future.
Anti-asthma drugs may be classified in the
following categories:
* Symptom-modifying (‘relievers’, e.g. bronchodi-
lators).
These products act by relaxing smooth muscle
and thus improving airflow through the conduct-
ing airways.3 Registration of this class of drug
requires demonstration of a beneficial effect on
objective measures of airflow (e.g. FEV1, PEFR),
and on symptoms, with no detectable adverse
effect on the inflammatory process or progress
of the disease.
* Symptom preventers (‘controllers’).
These products prevent or reduce symptoms
of asthma, generally by their effect on the
airway inflammatory process.3 Registration of
this class of drug requires demonstration of
benefit in symptomatology, disease control,
lung function, exacerbations and/or quality
of life, supported by evidence of relevant
pharmacological effects on the inflammatory
process in vivo.
* Disease-modifying agents.
Currently no products are available with a
demonstrable effect on the progress or severity
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of asthma or for prevention in patients at risk of
the disease. Registration of products that would
affect the progress of asthma would require
long-term studies, demonstrating a change in
the severity rating of the disease in a significant
number of patients. Registration of drug pro-
ducts to prevent asthma developing would
require long-term studies in patients identified
as at high risk of developing asthma (predomi-
nantly children). Sensitive and accurate prog-
nostic tools and a placebo group would be
important elements in registering this type of
drug product.
* Structure-modifying agents.
Currently there are no products that demon-
strate a effect on the structural changes seen in
chronic asthma (‘airway remodelling’) and the
progress or severity of disease. Registration
would require direct evidence of structural
effects (from bronchial biopsy or imaging tech-
niques) together with evidence of associated
benefit (improvement in lung function or symp-
toms, reduction in use of other medications) and
a prolonged absence or reduction of objective
signs and symptoms of disease. The development
programme should also demonstrate that there
is no long-term decline in lung function or
increase in bronchial hyper-responsiveness
(BHR).
Preclinical studies
In vitro and in vivo studies should be conducted to
provide some scientific rationale for use of an
experimental asthma drug in human studies.
Guidance on the preclinical safety testing, includ-
ing tests for reproductive toxicity, genotoxicity and
carcinogenicity and advice on the design of
toxicokinetic studies are available in reports from
the International Conference on the Harmonisation
of Technical Requirements for Pharmaceuticals
(ICH) (www.ifpma.org).
In vitro tests are of use in high throughput testing
and in ascertaining the biological responses of
compounds, however, in vivo studies are generally
more informative. Although there is no animal
model that reproduces the chronic relapsing and
remitting features of human asthma, animal mod-
els can display some pathological features of the
asthmatic process.4 Presently, there are no animal
models with which to assess potential disease-
modifying drugs. In the future genetically modified
animals may provide more representative models
of human asthma.
Clinical trials
Diagnosis and inclusion criteria
Diagnosis
It is necessary to ensure that a patient population
for a trial is homogenous. Diagnosis should be based
on age, history, symptoms and signs, airway
observations over time and current treatment and
control.
In the GINA guidelines,3 asthma severity is
divided into intermittent, mild persistent, moder-
ate persistent and severe persistent. The classifica-
tion of severity is complicated by the fact that
many patients are treated with anti-inflammatory
agents such as inhaled corticosteroids, and, be-
cause of the risks associated with discontinuation,
the judgment of the level of severity of asthma is
often made in the presence of inhaled corticoster-
oid therapy.
Exacerbations have been defined as episodes of
worsening of asthma with a predetermined in-
crease in symptoms and a fall in PEFR. A severe
exacerbation is usually defined as one that requires
oral corticosteroids as judged by the clinical
investigator, or an episode in which morning PEFR
falls by more than 30% from mean baseline PEFR on
at least 2 consecutive days.5
Airway observations include variability in airflow
limitation, and an increase in FEV1 following
inhalation of a short-acting b-agonist of at least
12% of the baseline value is a commonly used
measure.6 In the presence of severe airflow obstruc-
tion, such as a baseline FEV1 of less than 1 l, an
increase of 200ml is considered significant. Peak
expiratory flow rate (PEFR) may also be used,
requiring an increase of at least 60 l/min to confirm
a diagnosis of asthma. In monitoring lung function,
FEV1 compared with PEFR is a robust measurement
being highly repeatable. Measurements such as the
ratio of residual volume to total lung capacity (RV/
TLC), slow vital capacity (SVC) and trapped gas
volume measurements could be helpful as suppor-
tive data in understanding the nature and extent of
the disease.
Inclusion criteria
In Phases II and III trials, a broad range of patients
should be included based on baseline lung function,
e.g. baseline FEV1 between 45% and 85% of
predicted. Additional randomisation criteria such
as the requirement for a minimal level of symptoms
at run-in and the absence of a recent exacerbation
for 6 weeks prior to enrolment will secure sufficient
scope for improvement. Level of severity may
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be stratified, for example by taking into account the
degree of symptoms, or baseline FEV1 or the amount
of corticosteroid therapy. Co-morbidities such as
rhinitis, simusitis and gastro-oesophageal reflux
occur in association with asthma and should be
recorded because these may confound the treat-
ment effect. Atopy, defined by positive skin prick
tests to common aero-allergens and the measure-
ment of serum IgE, may be important when certain
specific agents are being tested. The inclusion or
exclusion of smokers needs to be considered.
Provocation tests in humans
Most provocation tests are done early in the devel-
opment of new anti-asthma compounds as proof-of-
concept studies for decision-making purposes.
Such testing requires rigorous and distinct ex-
perimental protocols for each of the various
bronchoconstrictor stimulae7 as well as standar-
dised methodologies for data analysis.8
Antigen challenges
Bronchial allergen challenges: Following allergen
inhalation, in asthmatics with specific sensitisation
to that allergen, IgE-mediated cells rapidly release
histamine, prostaglandins and leukotrienes leading
to bronchoconstriction. This early asthmatic re-
sponse (EAR) (20% fall in FEV1 from baseline)
gradually improves over the next 2 h.9 In approxi-
mately 50% of subjects, a late asthmatic response
(LAR) is seen 2–4 h after challenge and may last up
to 24 h. Traditionally, a decrease in FEV1 of 415%
from baseline between 4 and 12 h after challenge is
considered diagnostic of LAR. Although most of the
currently available anti-asthma drugs show bene-
ficial effects on the LAR, there is considerable
debate as to what predicts the development of the
LAR and the relevance of this model to clinical
asthma is questioned.10
Nasal allergen challenges: Reproducible nasal
symptoms and cellular recruitment are induced in
nasal secretions11 which make them suitable for a
cross-over study. The advantages of the nasal
allergen challenge model compared to the bron-
chial challenge model are that the nasal challenge
model is safer, easier to perform, and easier to
repeat, and nasal mucosa is easily accessible for
repeated measurements. The disadvantage is that
nasal challenge is not a direct assessment of
bronchial reactivity, but a surrogate.
Exercise challenges
The degree of protection afforded by a drug
against exercise-induced bronchoconstriction may
be used to assess therapeutic benefit in patients
with mild asthma who have minimal symptoms
and near-normal airway function. Although the
pathogenesis of exercise-induced bronchoconstric-
tion is incompletely understood, airway cooling
and drying are thought to release inflammatory
mediators leading to airway smooth muscle
constriction.
Non-specific challenges
BHR is a characteristic feature of asthma that is
sensitive to reliever and controller drugs. BHR can
be measured by inhalation challenge testing with
methacholine, histamine, leukotrienes, bradykinin,
or adenosine monophosphate (AMP) as well as after
exposure to non-pharmacologic stimuli such as
hyperventilation with cold dry air, SO2, and inhala-
tion of hypertonic or hypotonic aerosols.
Negative and positive predictive values
In allergic asthma, dissociation between airway
inflammation, airway function and airway hyper-
responsiveness has been reported12 suggesting that
the effects of therapy should not be assessed by a
single provocation test. If adequately powered,
measurements of airway function, airway inflam-
mation and BHR can be done before and after
antigen challenge in a single clinical study. At the
end of the study, changes from baseline can be
compared between treatment groups (placebo or
active comparator). A negative provocation test is
not necessarily indicative of a lack of activity. On
the other hand, positive results in such tests
probably indicate a good chance of positive out-
come in confirmatory therapeutic efficacy studies
since the compound has shown beneficial effects
under difficult conditions.
Therapeutic trial design
Classically, pivotal trials should be randomised,
parallel group, double blind and controlled. In
Western Europe most asthmatics with moderate or
severe disease are treated with inhaled corticos-
teroids and this treatment should not be with-
drawn. This problem can be addressed by the use of
an add-on design. Trials with comparators are
recommended as part of the registration dossier in
Europe. Comparison to reference therapies is
needed for pharmacoeconomic purposes. The choice
of comparator depends on the treatment goal for
the drug and the target claims. Classical compara-
tors, such as inhaled corticosteroids for anti-
inflammatory controller therapy, are advocated.
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Duration
The duration of asthma trials depends on the
treatment strategy and should be tailored to the
outcome and intended labelling, as below:
* studies in acute severe asthma may require a
study duration of only a day or days,
* for regular, or as needed, use of bronchodilators,
short term trials (6–12 weeks) may be used,
* for controller therapies, trials lasting at least 3
months are necessary,
* for a study of exacerbations, trials should be
extended to a minimum of 6 months,
* therapies that target the underlying structural
changes or the course of the disease, will need
longer-term trials of at least a year and
consideration should be given to a follow-up
period after drug withdrawal to ascertain per-
sistence of effect,
* disease-modifying drugs impacting the natural
history of the disease may require several years
of study.
Dose: response trialsFPhase II
The general principles of ‘‘dose response informa-
tion to support drug registration’’ are contained in
ICH E4 (www.ifpma.org). Design and interpretation
of these studies can be enhanced by information on
mechanism of action, drug affinity to the target and
drug metabolism and pharmacokinetics.
Administration of a drug by the inhaled route, as
frequently used for asthma, brings an additional
level of complexity. Drug effectiveness for inhaled
medication is largely a measure of topical activity
while safety relates to both local and systemic drug
effects. Dose–response relationships, particularly
for inhaled drugs, may be complicated by asthma
severity (which influences the site and extent of
drug deposition) and disease variability. Lack of
differentiation between doses may reflect the large
inter-subject variability of the inhaled dose deliv-
ered (as reflected in plasma concentrations),
sensitivity to end points,13 and duration of the
study (influence of onset of action and time to
maximal response). It is prudent to choose the
therapeutic doses of an investigational drug in
Phase II dose ranging using the same end points to
be used in the Phase III trials.
Confirmatory trialsFPhase III
* Equivalence or non-inferiority design:
Equivalence studies test the clinical hypothesis
that agents (usually a new and a standard
therapy) differ to an extent that is clinically
unimportant. Non-inferiority trials test the
hypothesis that the new agent is at least not
inferior to the standard treatment by a pre-
specified amount. In equivalence or non-infer-
iority trials similar weight is given to the per-
protocol and the intent-to-treat analysis.
Equivalence trials usually require that the 95%
confidence interval for the difference between
treatments be within some a priori clinically
important treatment boundary. Equivalence or
non-inferiority trials are generally necessary for
the assessment of a new delivery device for the
same inhaled drug, but may also be used to
compare 2 drug therapies of the same class (ICH
E10, www.ifpma.org).
* Cross-over design:
In general, cross-over designs should not be used
for confirmatory asthma trials, due to the
variability of the disorder. However, they may
be used to understand better the mechanisms of
a treatment or to investigate the heterogeneity
of responses to treatment.
* Add-on versus monotherapy design:
The ideal evaluation of a new drug for asthma
would be a monotherapy trial, however, in
practice it is difficult to recruit any but the
mildest asthmatics who are not already receiving
maintenance therapy, e.g. inhaled corticoster-
oids. Thus, either the current therapy has to be
withdrawn and substituted by the test agent or
an add-on design must be adopted. In an add-on
study patients are randomised to receive the
test agent or placebo in addition to their current
anti-asthma therapy. It is desirable to recruit
patients who are all on the same maintenance
therapy, e.g. low dose inhaled corticosteroids,
or at least to stratify for different treatment
regimens.
* Withdrawal (sparing effect) design:
The withdrawal of a controller drug, usually oral
or inhaled corticosteroids, under the cover of
the test therapy or placebo, is helpful but may
pose difficulties in recruitment. In particular, the
run-in period during which the minimum effec-
tive dose should be established is usually too
short and most withdrawal studies have shown
that the minimum effective dose was not
reached. Steroid sparing may also be used as a
secondary endpoint to support key efficacy
claims but does not necessarily lead to a claim
itself. Add-on and corticosteroid-sparing compo-
nents can be combined into a single trial.
* Effectiveness design:
Real life, pragmatic or effectiveness trials should
not be used for confirmatory efficacy but may
provide useful supportive data and are helpful in
confirming the safety profile. In these trials,
broader cohorts of asthma patients are treated in
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the absence of disease-related exclusion criteria.
In pivotal trials, the selection of patients usually
excludes ‘‘outliers’’ who may represent a large
part of a population of asthmatics, e.g. tobacco
smokers. Co-morbidities (e.g. rhinosinusitis) and
health economics can also be taken into account
in effectiveness studies.
Outcome measures
End-points used to determine drug effectiveness have
been influenced by knowledge of the pathogenesis of
asthma and mechanisms of action of current thera-
pies. Bronchodilator-induced improvements in end-
points such as FEV1 and PEFR correlate well with
improved asthma symptoms and therefore objective
measures of lung function became the standard both
in clinical practice and regulatory assessment.14 With
the hypothesis that pulmonary inflammation causes
asthma and with the advent of new mechanism-based
drugs, interest has focused on asthma exacerbations
and patient-centred measures as important endpoints
for testing new therapies. For many drugs, co-
primary endpoints combining lung function and
patient-centred outcomes should be used in con-
firmatory efficacy studies. The minimal important
changes for many asthma clinical trial assessments
have been established.15
Symptoms
Patients recognise a number of symptoms including
cough, wheeze, chest tightness and dyspnoea. In
clinical trials patients self-report their symptoms
on diary cards. With increasing focus on asthma
control this reporting system is being supplemented
by other patient-centred outcome measures, espe-
cially composite scores of asthma control.16 Symp-
tom scores or composite endpoints require clinical
validation to be acceptable for registration.
Lung function
There is a variety of methods used to measure lung
function including spirometry measures (FEV1 and
FVC) and PEFR. FEV1 has several advantages, being
robust, repeatable, standardised, easy to perform
and reflecting airway calibre. PEFR is easier to
perform, and enables an objective measure to be
made by the patients themselves at frequent
intervals, however is a less reliable measurement
than FEV1 because it is not observed in the clinic. In
more severe disease the peripheral airways, in-
cluding the alveoli, may become involved and FEV1
better reflects airflow in the more distal genera-
tions of the bronchi than PEFR but is still not an
adequate assessment of the peripheral airways.
Neither FEV1 nor PEFR are sensitive to obstruction
in the lung periphery and other measures of lung
function, such as the ratio between residual volume
and total lung capacity, a SVC or inspiratory
capacity, may be useful in assessment of this
‘‘silent’’ area of the lung in asthma.
Reduction in concomitant medication
In clinical trials the use of a concomitant medica-
tion, usually a short-acting inhaled bronchodilator
(prescribed for immediate relief of symptoms), is
an additional useful outcome measure. Reduction
in use of such medication will confirm an improve-
ment in lung function and symptoms. Similarly,
reduction in inhaled or oral corticosteroid usage,
when trial medication is added to the treatment
regimen, is also used as an outcome measure.
Establishment of a baseline corticosteroid dose,
inherent variability of the disease and clinical
relevance of observed reductions are challenges
with this outcome measure.
Exacerbations
The definition of exacerbations in asthma combines
the occurrence of symptoms, impairment in air-
flow, and medication needs. Frequency, duration
and severity need to be considered. Changes in
concomitant medication will reduce the relevance
of exacerbation measurements.
Quality-of-life
Quality-of-life (QoL) measurements may be in the
context of general health, or asthma specific.
General health measures such as the SF-36 are
standardised, but they may not be responsive
enough to identify small but clinically important
changes in asthmatic patients’ quality of life.17
Asthma-specific questionnaires are available for
adults, adolescents and children and the degree of
change considered to be of minimal clinical
relevance has been identified.18
Measurements of inflammation and airways
pathology
Surrogate endpoints using biomarkers to demon-
strate disease progression would greatly facilitate
the development of disease-modifying drugs. More
comprehensive and sophisticated analyses involving
genomics or proteomics may offer this in the future.
Evaluation and analysis
Interpretation of results cannot rely on statistical
significance alone but needs to include the clinical
relevance of any changes, taking account of expert
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clinical opinion, in the context of adequately
powered prospective studies.
The use of surrogates and non-clinical markers of
disease activity is to be encouraged particularly in
early drug development and to characterise the
pharmacodynamic activity in relation to clinical
efficacy parameters. Care needs to be taken not to
over-interpret findings (e.g. anti-inflammatory ef-
fects based on isolated findings) and conclusions
need to be made in the context of the population,
study design and surrogate/disease marker.
Published systematic reviews of asthma treat-
ments, which included meta-analyses, have been
criticised.19 The use of meta-analyses for the
evaluation of therapies for regulatory submissions
is considered in a draft guideline (www.e-
mea.eu.int). This states the accepted regulatory
purposes for meta-analysis, several which could be
utilised in the development of an asthma therapy.
Ideally, the meta-analysis should be prospectively
planned as part of the clinical development
programme. The meta-analysis protocol details
the key aspects to be undertaken very much in
the same way as a study-related protocol. Retro-
spective meta-analyses may be acceptable but only
when stringent prerequisites can be fulfilled. The
meta-analyses need to be assessed with regard to
both the clinical significance and robustness of the
findings.
Special situations
Acute severe asthma
Acute severe asthma may be life-threatening. It
may develop over days or rapidly over minutes.
Patients are usually in varying degrees of distress
with dyspnoea and chest tightness, and may have
difficulty in speaking full sentences. Peak flow
measurements are severely reduced, usually by
more than 50%. Significant hypoxaemia is present,
with either hypocapnia, or during severe episodes,
hypercapnia.
These patients should be treated in hospital.
Standard therapy for these episodes consists of
oxygen therapy, rapid-acting bronchodilators and
corticosteroids. There are few published trials on
the optimal timing and dosing of corticosteroids,
and some recent studies indicate that the recom-
mended doses of intravenous hydrocortisone are
unnecessarily high.
Studying newer agents in the treatment of acute
severe asthma is not easy. It is difficult to use
alternative treatments in a situation that is
potentially life-threatening. In this regard, studies
of newer agents may need to be performed in
addition to standard therapy where endpoints are
either spirometry, need for additional standard
therapy, or clinical outcomes. The sample sizes
required for adequate power may be large, making
these difficult, expensive, time-consuming, and not
routine. However, there is a medical need for new
therapies in acute severe asthma and additionally,
adequate trials of existing therapies along with
analytical work, such as endpoint validation and
severity definitions, are required.
Paediatric asthma
Children exhibit important age-related differences
in anatomy, physiology, pathology, development
and drug metabolism from adults, as well as in
social and emotional factors. Therefore, pharma-
codynamics and kinetics should be addressed
separately in paediatrics.
The pathology of asthma is often less progressed
in children, with a smaller degree of airway
remodelling, that may be reflected in differing
responses to treatment. Paediatric asthma is
generally less severe than in adults, with inter-
mittent and mild persistent disease characterising
the majority of patients. Therefore, response to
treatment may differ from the response observed
in adult patients with longer standing chronic
disease and should be studied separately.
Lung function is normal (or can be normalised by
therapy) in between symptomatic episodes in the
majority of paediatric asthma. Therefore, study
inclusion may often rely upon the documentation of
bronchial reactivity, using the number of episodes
of bronchoconstriction for example as an endpoint.
Treatment and outcome measures need to be
appropriate to the age of the child, using the ICH
classification of paediatric age ranges (www.
ifpma.org). Techniques for evaluating lung function
in infants and young children should use effort
independent methods validated in these age-
groups. Questionnaires and diary cards may need
to be completed by parents/carers and will require
separate validation for infants, pre-school, and
schoolchildren.
Asthma in the elderly
There are several problems with respect to both
diagnosis and management that make asthma in the
elderly of special consideration. A major problem in
this age group is the certainty of the diagnosis,
particularly in differentiating it from chronic
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obstructive pulmonary disease (COPD) and other
conditions such as congestive cardiac failure,
endobronchial neoplasm or pulmonary fibrosis.
Diagnosis can be defined as significant reversi-
bility to inhaled bronchodilator b-adrenergic ago-
nist, taken as an increase in FEV1 of 15% or of
200ml, whichever is greater, the latter particularly
in the presence of significant baseline airflow
obstruction.
Satisfactory control of symptoms is not usually
adequately achieved in this group of patients. Self-
monitoring of peak flows and symptoms is usually
not a problem, although incoordination due to
arthritis, muscle weakness, neurological problems
or deteriorating cognitive and mental ability may
lead to poor usage of inhalers. Many elderly
patients with moderate to severe airways obstruc-
tion are prescribed home nebulisers for adminis-
tration of b-agonist bronchodilators. Glucocorticoid
therapy is of proven benefit, but the potential for
systemic side-effects may be more prevalent in the
elderly. Use of oral corticosteroid therapy may also
be associated with greater probability of glucose
intolerance, systemic hypertension, cataracts and
osteoporosis, which are all more common in the
elderly. Oral therapy has special considerations
since there may be changes in metabolism of drugs
due to ageing or concomitant disease processes,
and potential for interactions with other drugs
taken. This highlights the need to consider the
inclusion of elderly patients in therapeutic trials of
new therapies.
Co-morbidity
Epidemiological studies have shown that at least
60–70% of asthmatics also experience rhinitis and
20–30% of patients with allergic rhinitis also have
asthma. Asthma can also co-exist with COPD. The
airflow obstruction of COPD may either be totally
non-reversible or partially reversible with an anti-
cholinergic or b-adrenoceptor bronchodilator.
Other co-morbidities that impact upon asthma are
gastro-oesophageal reflux and chronic sinusitis.
Asthma is also susceptible to the influence of sex
hormones, particularly progesterone which might,
in part, explain why chronic severe asthma is more
frequent in adult women whereas, in children,
asthma predominates in males. Usually patients
with co-morbidity are excluded from clinical
studies. However, real patients have such co-
morbidities and trials are needed in this area.
These may be done in late-stage development or
during effectiveness studies.
Inhaler devices
Inhalation therapy is widely used for the treatment
of asthma. An ideal device should deliver a
reproducible, pre-determined dose of drug to the
lung and should have minimal deposition of drug
other than in the lung so that minimal systemic
effects occur.3 The CPMP is close to publishing
guidance on the pharmaceutical requirements for
both dry powder inhalers and metered dose
inhalers. Similarly, the European Committee for
standardisation (CEN) has drafted procedures for
the evaluation of nebulizing systems and their
components.
The most commonly prescribed inhalation de-
vices include pressurised MDIs with or without
spacers, dry-powder inhalers, and nebulisers.
There are large differences in design and per-
formance between the various devices. The
characteristics of each individual drugþ device
combination should be carefully assessed by
both in vitro and in vivo methods. This should
require clinical testing, depending on the accept-
ability and robustness of the surrogate in vivo
methods.
Lung dose from inhaled drug delivery is impor-
tant to establish, as it determines the efficacy
and risks of treatment. Such information may
be obtained from animal models, pharmaco-
kinetic studies and from imaging techniques.
Gamma scintigraphy, which provides only 2-D
imaging, may be use to estimate lung depo-
sition. However, potentially more robust 3-D
techniques include single photon emission com-
puted tomography (SPECT) and positron emission
tomography (PET). 3-D imaging assesses more
accurately regional deposition patterns in the lung.
Further validation of these imaging techniques
is required.
The standard in determining clinical efficacy
and bioequivalence between delivery systems
remains the chronic dosing clinical trial. Pharma-
codynamic studies such as challenge studies may
be an alternative for particular classes of mole-
cules such as beta agonists. Well-powered and
adequately designed clinical trials to show non-
inferiority or equivalence should normally be
performed. Clinical trials also help in provi-
ding data to guide the prescribers on substi-
tution of different devices containing the same
drug.20
It is not generally possible to extrapolate directly
from data in adults to children. Data should be
generated to show that the device can be used by
children and that the inspiratory flow rate needed
is achievable by the targeted age group.
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Safety
Core safety assessments required during preclinical
and clinical development include:
* in vitro genotoxicity/mutagenicity,
* animal fertility and embryotoxicity studies,
* acute and chronic animal toxicology (the latter
in two different mammalian species),
* recording of sought and volunteered adverse
reactions during clinical studies,
* routine physiological and laboratory screening,
e.g. electrocardiography (ECG), serum haema-
tology and biochemistry.
Additional assessments may be indicated, based on
the findings from preclinical research or on the known
pharmacology and toxicology of the drug class. There
are some special aspects of asthma therapy which
necessitate specific safety assessments:
Patient population: asthma is particularly pre-
valent in younger people, so potential drug effects
on growth, development, maturation, and fertility
are important. In elderly patients adverse effects
related to concomitant disease (e.g. impaired
hepatorenal function) or its treatment (potential
drug interactions) are important.
Inhaled therapeutics: specific preclinical inhala-
tion toxicology studies are mandatory. All inhaled
medications have the potential to cause bronchos-
pasm; this is often related to non-drug components.
The potential for inducing bronchospasm should be
evaluated during patient studies, measuring expira-
tory flows before and 5min after drug administra-
tion. A drop of 15% in FEV1 or 20% in PEFR is taken as
a positive test. Patients receiving inhaled proteins in
clinical trials should be monitored for symptoms
suggesting an immune-modulated pneumonitis/al-
veolitis (cough, fever, dyspnoea) that would man-
date appropriate investigation (lung imaging,
measurement of gas transfer factor).
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